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Urogenital schistosomiasis-induced 
squamous cell carcinoma of the 
bladder
Schistosomiasis is a major neglected tropical disease 
(NTD) and is considered the most important human hel-
minth disease in terms of morbidity and mortality.1,2 
Control strategies have been used to block transmission and 
reduce the burden of this NTD, including mass targeted 
chemotherapy, improvements to sanitation, modification of 
the environment, and use of molluscides.2,3 Although dif-
ferent approaches to control, prevent, or in some cases even 
eliminate NTDs exist, like water purification or mass drug 
administration, for many of them, the tools and implemen-
tation strategies available are suboptimal, incomplete, or 
inadequate to sustain elimination effectors.1,4 Chemotherapy 
against flatworm infections, such as schistosomiasis and 
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Abstract
Urogenital schistosomiasis is a neglected tropical disease that can lead to bladder cancer. How urogenital schistosomiasis 
induces carcinogenesis remains unclear, although there is evidence that the human blood fluke Schistosoma haematobium, 
the infectious agent of urogenital schistosomiasis, releases estradiol-like metabolites. These kind of compounds have been 
implicated in other cancers. Aiming for enhanced understanding of the pathogenesis of the urogenital schistosomiasis-
induced bladder cancer, here we review, interpret, and discuss findings of estradiol-like metabolites detected in both 
the parasite and in the human urine during urogenital schistosomiasis. Moreover, we predict pathways and enzymes 
that are involved in the production of these metabolites emphasizing their potential effects on the dysregulation of the 
tumor suppressor gene p53 expression during urogenital schistosomiasis. Enhanced understanding of these potential 
carcinogens may not only shed light on urogenital schistosomiasis-induced neoplasia of the bladder, but would also 
facilitate development of interventions and biomarkers for this and other infection-associated cancers at large.
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opisthorchiasis, is constrained by the limited number of 
indicated drugs in the market, generally only praziquantel. 
Emerging drug resistance has been already reported.5 Yet 
schistosomiasis remains a major public health problem 
especially in endemic rural regions of sub-Saharan Africa.6 
Eggs are shed continuously by the Schistosoma haemato-
bium adult parasites; these eggs engender chronic, granu-
lomatous inflammation in the bladder wall, leading to 
severe disease including malignancy (Figure 1).7 Indeed, 
bladder cancer is a frequent and grim complication of 
chronic urogenital schistosomiasis (UGS).8 The World 
Health Organization’s International Agency of Research 
Cancer (WHO IARC) categorizes infection with S. haema-
tobium as a definitive etiology of cancer, that is, Group 1 
carcinogen.1,9 The severity and frequency of squamous cell 
carcinoma (SCC) of the bladder are related to the burden 
and duration of the infection.8,10 Understanding the mecha-
nisms underlying the S. haematobium infection-related car-
cinogenesis is a key element to define targets for novel 
control tools-vaccines or new drugs to combat the infection 
and its consequences.11
Estrogen-DNA adduct-mediated pathways may underlie, 
at least partly, the etiopathogenesis of the UGS-induced 
bladder cancer.12–16 Interactions between the estrogen recep-
tor (ER) and total antigen preparation of S. haematobium 
have been described in vitro. Chinese Hamster Ovary 
(CHO) cells transfected with a construct expressing lucif-
erase driven by the estrogen response element (ERE) were 
exposed to S. haematobium adult worm antigen preparation. 
Luciferase activity measured in cells exposed to S. haema-
tobium antigens was significantly lower than controls, 
suggesting that the antigen preparation downregulated and 
repressed the ER activity at least in vitro.13 Downregulation 
of ER-alpha and ER-beta may serve to control physiological 
responses in target tissues.17 These findings suggest that 
total antigens dampen the stimulatory response to estra-
diol.12 In addition, schistosome may synthesize estrogen-
like metabolites, and derived estrogen-DNA adducts that 
circulate in the blood may be excreted in the urine during 
UGS.12,13 The causes and consequences of the formation of 
these estrogen-derived metabolites, and whether they might 
promote DNA damage in the bladder urothelium and/or other 
host tissues remain unclear. Estradiol-like metabolites and 
novel metabolites of 8-oxo-2′-deoxiguanosine (8-oxodG) 
were detected in urine of UGS and associated SCC of the 
bladder cases;15 8-oxodG liberated following oxidation of 
deoxynucleotides, has been implicated in the initiation and/or 
promotion of inflammation-mediated carcinogenesis, and is 
indicative of chromosomal damage.15,18,19 Trapped eggs in 
bladder tissue induce a distinct immune-mediated granu-
lomatous response that causes local and systemic pathologi-
cal effects that along with resulting bacterial superinfection 
and renal dysfunction also can have lethal consequences.2 
Mutations and/or expression dysregulation of p53 gene have 
been associated with benign and premalignant lesions and 
histologically normal mucosa adjacent to the SSC tissue, dur-
ing UGS-induced carcinogenesis.20 Determining whether 
these mutations in p53 are related to the presence of estrogen-
DNA adducts might be instructive.20
The tumor suppressor gene p53, located on chromo-
some 17p13, is a frequent target for mutations commonly 
involved in tumor progression in diverse neoplasias.21,22 
Diverse roles for p53 have been described, including cell 
cycle control, DNA repair, activation of apoptosis,23 inhi-
bition of tumor growth, suppression of cell transforma-
tion,24 and maintenance of genome integrity.25–27 Loss or 
mutation of p53 accelerates tumorigenesis and alters the 
cell response to agents that damage the DNA.22 In particu-
lar, several mutations in p53 have been associated with 
UGS-induced bladder cancer, for example, mutations in 
the coding region, codon 249, were identified in dysplasic 
and metaplasic lesions in the urinary bladder or frequently 
in invasive SCC of the bladder.19,21,28,29
Here, we propose a pathway for the formation of these 
estrogen-like metabolites and describe key enzymes based 
on recent findings.12–16 Emphasis is given to the tentative 
association between these metabolites, dysregulation of 
p53 and DNA damage in the target tissue—the urothelium 
of the urinary bladder-during UGS. Estradiol-like, cat-
echol-like, and/or oxysterol-like metabolites play a role in 
carcinogenesis as potential initiators of chemical carcino-
genesis,15,30 and several mechanisms may explain their 
role in the disease. The hormone-mediated mechanism by 
which the ER is stimulated by some of these metabolites 
promoting cellular proliferation, increasing the likelihood 
of errors in DNA replication, has been well studied. 
Figure 1. (a) Representative case of urogenital schistosomiasis 
(UGS)-induced bladder cancer, in a patient residing in an 
endemic region of UGS in Northern Angola. Arrow indicates 
the affected area, (b) representative micrographs of eggs of S. 
haematobium, both viable (A) and calcified (B) and (c) Histology 
of bladder mucosa revealing eggs of S. haematobium (asterisks).
Vale et al. 3
Alternatively, estrogen metabolites acting as chemical car-
cinogens might react covalently with the DNA by redox 
cycling or by forming an abasic site. Subsequent error-
prone repair of the damaged DNA eventually results in 
chromosomal lesions that initiate carcinogenesis.14,30–33
Pathways for formation of estrogen-
like metabolites
Novel, estrogen-derived compounds, recently reported,12–15 
are based on the steroid core cyclopentanophenanthrene-
4-ring, that is, similar to cholesterol, a precursor of bile 
acids, and steroid hormones including estradiol.34 It is fea-
sible that S. haematobium produces estradiol-related com-
pounds, given that this parasitic flatworm may have 
evolved orthologous genes to those in mammals involved 
in estrogen metabolism.35 Estradiol-like metabolites of 
schistosome origin may underlie the development of SCC 
of the bladder during UGS.36
Mammalian and related hormones, estrogen-
like metabolites, and schistosome physiology
Whereas mammalian host hormones are required for the 
survival, development, and differentiation of schisto-
somes, the underlying molecular mechanisms remain 
unclear.36,37 The Asian schistosome, Schistosoma japoni-
cum, expresses receptors for steroid hormones displaying 
pathways for processing steroid hormones to anabolize 
derivatives.38 The schistosome genome encodes putative 
enzymes that could convert progesterone and pregne-
nolone to estriol, estrone androsterone, and testosterone. 
Hence, schistosomes might exploit this pathway during 
their parasitic developmental stages.38 A gene encoding an 
ortholog of 17β-hydroxysteroid dehydrogenase has been 
identified in the genome of S. haematobium. Orthologs 
of 17β dehydrogenase also occur in S. mansoni and S. 
japonicum, but given that the infection with these species 
of schistosomes has not been associated with cancer devel-
opment, unlike the chronic infection with S. haemato-
bium,36 among other factors, it is not unreasonable to 
speculate that specific host tissues exposed to S. haemato-
bium eggs, that is, urothelium, might be more susceptible 
to DNA damaged induced by these metabolites than host 
tissues exposed to S. mansoni and S. japonicum eggs, that 
is, liver and intestine.35 Moreover, the genomes of these 
three schistosomes likely encode orthologous enzymes 
involved on steroid biosynthesis and steroid hormone bio-
synthesis pathways (Supplementary Figures S1 and S2). 
Characterization and functional analysis of these enzymes, 
summarized in Tables 1 and 2, employing functional 
genomic tools such as transgenesis, gene silencing, and 
CRISPR-Cas9-mediated genome editing might provide in 
the near future insights in their biological roles in the host-
parasite relationship including in UGS-induced SCC.39–41
Role of P450 and reactive oxygen species 
(ROS) in the synthesis of metabolites
Steroid-related molecules may be metabolized into catechol-
like compounds (intermediately producing ROS) that react 
with DNA via Michael addition forming DNA adducts and 
creating apurinic sites that could eventually lead to muta-
tions further initiating a carcinogenesis process. Diverse 
cytochrome P450 enzymes play a key role both in the for-
mation of estrogen and its subsequent oxidative metabolism 
as well in cholesterol catabolism to bile acids,42 and also as 
a source of ROS.43 The oxygenated metabolites of estrogens 
represent structures with newly generated hydroxyl and 
keto functions at specific sites in the steroid nucleus, which 
are analogous to other steroid categories that undergo oxida-
tive metabolism, specifically androgens, vitamin D, and bile 
acids.44 As shown in Figure 2, the conversion of catechol 
semiquinones to quinones, performed by these types of 
Table 1. Orthologs of enzymes of the steroid biosynthesis pathway encoded in the genomes of Schistosoma haematobium and S. 
mansoni.
Enzyme ID Name S. haematobium S. mansoni
E-value Acc. no. E-value Acc. no.
1.14.13.70 Lanosterol 14-alpha demethylase 1.30E−44 A 06730 9.00E−52 Smp 008450.1
1.3.1.70 Delta14-sterol reductase 1.30E−31 A 07198 7.30E−38 Smp 124300.1
1.14.13.159 Vitamin D 25-hydroxylase 5.70E−11 A 00472 – –
1.3.1.21 7-Dehydrocholesterol reductase 5.80E−24 A 07198 3.90E−33 Smp 124300.1
3.1.1.13 Lysosomal acid lipase/cholesteryl ester hydrolase 1.10E−203 A 04656 2.50E−203 Smp 011000.1
2.3.1.26 Sterol O-acyltransferase 7.10E−257 A 03728 2.10E−273 Smp 134390.1
SMO1 4,4-Dimethyl-9beta,19-cyclopropylesterol-4alpha-
methyl oxidase
2.20E−22 A 07158 2.10E−30 Smp 074930.1
CYP51G1 Cytochrome P450, family 51 (sterol 14-demethylase) 1.30E−44 A 06730 9.00E−52 Smp 008450.1
FK Delta14-sterol reductase 1.30E−31 A 07198 7.30E−38 Smp 124300.1
DWF5 7-Dehydrocholesterol reductase 5.80E−24 A 07198 3.90E−33 Smp 124300.1
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Table 2. Orthologs of enzymes of the steroid hormone biosynthesis pathway orthologous enzymes encoded in the genomes of 
Schistosoma haematobium and S. mansoni.
Enzyme ID Name S. haematobium S. mansoni
E-value Acc. no. E-value Acc. no.
1.3.1.22 3-Oxo-5-alpha-steroid 4-dehydrogenase 1 3.50E−12 A 03363 – –
1.3.1.3 3-Oxo-5-beta-steroid 4-dehydrogenase – – 1.30E−69 Smp 150700.1
1.1.1.146 Corticosteroid 11-beta-dehydrogenase isozyme 1 – – 3.50E−14 Smp 186960.1
1.1.1.53 3Alpha(or 20beta)-hydroxysteroid dehydrogenase 8.40E−25 A 06678 5.50E−28 Smp 042680.1
1.1.1.62 17Beta-estradiol q7-dehydrogenase 1.00E−136 A 01343 2.20E−166 Smp 009430.1
1.14.14.1 Cytochrome P450, family 1, subfamily A, polypeptide 1 8.50E−15 A 00472 1.70E−12 Smp 156400.1
1.1.1.64 Testosterone 17beta-dehydrogenase (NADP+) 4.20E−46 A 05292 2.00E−46 Smp 168550.1
Figure 2. Hypothetical pathway for formation of molecules based on estrogen metabolism mediated by P450 enzymes in 
Schistosoma haematobium and in sera of persons with urogenital schistosomiasis. The initial step is oxidation of estrone (E1) 
to estradiol (E2) performed by 17β-HSD. E1 and E2 are metabolized to 2-hydroxy forms [2-OHE1(E2)], and then oxidized to 
catechol quinones [E1(E2)-2,3-Q]. P450 enzymes catalyze the conversion of catechol semiquinones [E1(E2)-2,3-Q] to quinones, 
which may release reactive oxygen species (ROS). Catechol quinones are reactive electrophiles capable of reaction with DNA 
bases, including adenine (Ade) and deoxyadenosine (dA) to form DNA adducts with structures compatible with m/z values 
established here (m/z 624, 738, 851, 963).
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enzymes, can also enter into redox cycling and, thereby 
release ROS.45 Accordingly, since S. haematobium exhibits 
P450 activity28 suggesting that it is able to produce catechol 
compounds that lead to formation of ROS, this may contrib-
ute to oxidative stress during UGS. Increased oxidative 
stress associated with schistosomes has been described.14 
When ROS accumulate and/or when antioxidants defenses 
are saturated, the negative effects of oxidants ensue.46 
ROS induce the oxidation of DNA bases to yield 
8-oxodG.18 Thus, P450 through oxidative metabolism 
could lead to both oxidative and DNA adducts, with 
mutagenic potential.31 The carcinogenic process in the 
bladders of the mice exposed to parasite antigens is 
independent of the effect of nitrosamines, findings 
indicating that schistosome antigens/metabolites 
induce inflammation.47
Estrogen-like metabolites and DNA adducts
There is a stepwise series in biosynthesis of estrogen from 
cholesterol. In brief, the biosynthesis commences with for-
mation of pregnenolone catalyzed by CYP11A. This is suc-
ceeded by the formation of the androgens androstenedione 
and testosterone, catalyzed by CYP17, and is completed 
when CYP19 catalyzes aromatization of androstenedione 
to yield estrone (E1) and estradiol (E2).48 Estradiol (E2) is 
mainly metabolized by (i) oxidation of hydroxyl function at 
the C-17 position to yield estrone (E1). 17β-Hydroxysteroid 
dehydrogenase (17β-HSD), a key enzyme in the metabo-
lism of estrogen,49 catalyzes this conversion. Estrogen is 
also metabolized by hydroxylation via cytochrome P450 
enzymes, preferentially on C2, C4, and C16 positions. 
When hydroxylation takes place on the steroid aromatic 
ring A, catechol estrogens are produced.50–52 CYP1A1, 
CYP1A2, and CYP3A4 participate in this process; they 
exhibit catalytic activity dominantly for the 2-hydroxyla-
tion in estrogen38 to liberate 2-hydroxyestrone/estradiol 
(2-OHE1(E2)). Thereafter, further oxidation to semiqui-
nones (E1E2-2,3-SQ) proceeds, and to quinones (E1E2-
2,3-Q) catalyzed by P450 enzymes. ROS also are liberated 
in this conversion. As electrophiles, catechol quinones 
form covalent adducts with DNA bases, such as adenine 
(Ade), and deoxyadenosine (dA), via Michael addi-
tion,29,31,52,53 giving rise to structures compatible with those 
with m/z values 624, 738, 851, and 963 that have been 
identified in the peripheral blood during UGS (Figure 2).13
Cholesterol is converted into bile acids through discrete 
enzymatic steps that include initiation of synthesis 
by 7α-hydroxylation of sterol precursors, ring structure 
modification, oxidation and shortening of the side chain, 
and conjugation of bile acid with amino acid.54,55 Microsomal 
cytochrome P450 enzyme cholesterol 7α-hydroxylase 
(CYP7A1) catalyzes the hydroxylation to yield 
7α-hydroxycholesterol.54 The product released from this 
hydroxylation is converted into 3-oxo Δ4 forms by 
microsomal 3β-hydroxy-Δ5-C27-steroidoxidoreductase 
(HSD3B7) and forms 4-cholesten-7α-ol-3-one.54 The 
enzyme CYP8B1, a sterol 12α-hydroxylase, promotes the 
12-hydroxylation leading to formation of 4-cholesten-7α-
12α-diol-one.54,55 Thereafter, AKR (aldo-keto reductase) 
family enzymes modify the aromatic ring. AKR1D1 and 
AKR1C4 act in concert, where AKR1D1 catalyzes 
5β-reduction of the 
bile precursor from 4-cholesten-7α-12α-diol-3-one to 
5β-cholesten-7α-12α-diol-3-one; AKR1C4 catalyzes the 
further reduction of ketogroups56 forming 5β-cholesten-3α-
7α-12α-triol. The next step is the side chain hydroxylation 
leading to form 5β-cholesten-3α-7α-12α-27-triol performed 
by CYP27A1. CYP27A1 introduces a hydroxyl group at 
C27 position and oxidizes this group to an aldehyde 
and subsequently to a carboxylic acid55,57,58 leading to 
3α-7α-12α-trihydroxy-5β-cholestanoic acid. Bile acid CoA 
ligase, CoA racemase, AcylCoA oxidase, D-bifunctional 
enzyme, and peroxisomal thiolase 2 modify the product to 
3α-7α-12α-trihydroxy-5β-cholan-24-one-CoA.55,56 The ter-
minal step of primary bile acids formation is the conjugation 
with an amino acid, usually glycine or taurine, and occurs in 
amide linkage on C24. Bile acid coenzyme A: amino-
N-acyltransferase catalyzes the reaction. The latter is a nota-
bly efficient enzyme, given that >98% of bile acids excreted 
from liver are amidated.59 The substrates are a bile acid 
coenzyme A thioesther (3α-7α-12α-trihydroxy-5β-cholan-
24-one-CoA) and glycine and taurine.59 The ultimate step 
liberates glycocholic or taurocholic acid.
As obligate parasites, the blood flukes likely evolved the 
capacity to exploit host hormones for their own needs, 
deploying the enzyme P450 to release E1(E2)-2,3-Q and 
related metabolites including catechols and other electro-
philes (Figure 2). These metabolites are generally inacti-
vated by conjugation reactions including methylation, 
glucuronidation, and/or sulfation. The common pathway of 
conjugation in extrahepatic tissues occurs by O-methylation 
catalyzed by the ubiquitous catechol-O-methyltransferase 
(COMT).53 If conjugation of catechol estrogens via meth-
ylation becomes insufficient, competitive catalytic oxida-
tion of catechol estrogen to catechol estrogen quinones can 
proceed.53 Alterations in the activity of phase I and phase II 
drug-metabolizing enzymes in the urothelium of the blad-
der during UGS might arise, interfering with the detoxifica-
tion of xenobiotics and other homeostatic processes. 
Indeed, diminished glutathione-S-transferase activity 
occurs during UGS.46 If homeostatic detoxification of cat-
echols was impeded during UGS, these metabolites might 
accumulate in the urothelium and elsewhere.
Pioneering reports indicated that schistosomes could 
not synthesize sterols de novo.60 However, this is contro-
versial given that lysates of schistosomes convert ster-
oids to related metabolites.42,61 Following infection of the 
skin penetration, the schistosomules migrate in the circu-
lation to the lungs, after which the parasites enter the 
6 Tumor Biology 
hepatic portal circulation or the vessels of the pelvic 
organs depending on the species; S. haematobium adult 
worms dwell in the venous plexus of the bladder and 
genital tract, whereas the other major human species 
dwell in the mesenteric veins.62
Catechol-like metabolites produced either by non enzy-
matic process (autoxidation by oxidative free radicals) or 
enzymatic catalysis42 might react with DNA bases to yield 
the molecules we have proposed (Figure 3). Based on 
recent findings,9,10,12,16 glycocholic acid may (1) lose the 
acidic moiety (-CH2COOH) and undergo hydroxylation 
then oxidation to produce the catechol-like compound m/z 
410; (2) lose oxo groups, and introduce a double bond on 
aromatic ring A to form the compound with m/z 366; (3) 
forms DNA adducts by reacting with DNA bases via 
Michael addition, m/z 716; (4) or after aromatic ring 
Figure 3. Possible pathway formation for estradiol-like metabolites reported in eggs and adult stages of Schistosoma haematobium and 
in urine of patients with urogenital schistosomiasis (UGS), derived from glycocholic acid (a) and taurochenodeoxycholic acid (b). The 
molecules with m/z 366, 410, 791 were observed in urine during UGS with or without bladder cancer. Metabolites with m/z 813 and 
817 were observed in schistosomes. The compound with m/z 803 was observed in urine during UGS and also within the parasite itself.
Vale et al. 7
modifications and further reaction with DNA bases to form 
m/z 803; or (5) undergo through a hydroxylation at C2 
position followed through an oxidation and then react with 
DNA forming m/z 813. This compound could undergo 
through a reduction of some hydroxyls group forming the 
compound with m/z 817 (Figure 3(a)). Other compound 
proposed (Figure 3(b)) differs in some ways from the 
above. Instead of a glycocholic acid, the precursor is a tau-
rochenodeoxycholic acid. The synthesis is similar to that 
for glycocholic acid, but this compound does not proceed 
through hydroxylation of CYP8B1. Rather than forming 
5β-cholesten-7α-12α-diol-3-one, 5β-cholesten-7α-ol-3-
one is liberated (Figure 3(b)). This product undergoes the 
same reactions of 5β-cholesten-7α-12α-diol-3-one, but the 
reaction conjugates the amino acid taurine instead of gly-
cine. The next step is the reduction of sulfonic acid moiety 
(-SO3H) of taurochenodeoxycholic acid to a thiol group 
(-SH). Again, this product could eventually react with 
DNA bases leading to the compound with m/z 791. The 
estrogen-like DNA adducts with m/z 716, 803, 813, 817 
have been described in S. haematobium;14 the remaining 
compounds highlighted here, m/z 366, 410, 791, have been 
seen in urine during UGS including cases with or without 
bladder cancer. In addition, the m/z 803 metabolite was 
identified in both eggs and other developmental stages of 
the schistosome, and in urine of patients with UGS.14,15
Consequences of estrogen-like 
metabolites
The formation of DNA adducts induces continuous DNA 
oxidation, leading to mutations and/or gene expression 
dysregulation of oncogenes and tumor suppressors, such 
as the overexpression of p53 observed during UGS.63 
Consequently, these metabolites of estrogens derived from 
the parasite might behave as chemical carcinogens.47 In 
addition, there may be “classical” hormone-like effects of 
these metabolites on the endocrine and immune system of 
the host; the ER activity was suppressed in urothelial cells 
cultured in vitro and in the bladders of mice exposed to S. 
haematobium antigens.64
The levels of oxidized DNA bases reflect a balance 
between the amount of oxidative DNA damage and 
DNA repair. It seems reasonable to assume that a subop-
timal repair of 8-oxodG would be mutagenic, and may 
be implicated in the initiation and/or promotion of 
inflammation-mediated carcinogenesis.47,65,66 During 
UGS, in the face of continuous shedding of parasite 
eggs into the wall of the bladder and egress of the eggs 
with the urine, sustained production of catechols is 
expected, with continuous generation of ROS that oxi-
dize DNA bases of urothelial cell chromosomes. 
Cavalieri and coworkers postulate that the presence of 
high levels of oxidized DNA suggests a carcinogenic 
mechanism induced by catechol estrogens.52 Among the 
compounds related to DNA adducts, we observed 
metabolites with m/z 285, 274, 265, 204, 190 (Figure 
4), derived directly of 8-oxodG in patients with UGS 
and UGS-induced bladder cancer.15 Higher levels of 
metabolites derived from 8-oxodG were identified in 
persons with UGS free of cancer than in patients with 
already advanced UGS-induced bladder cancer. Hence, 
we speculate that DNA oxidation may be more pro-
nounced during incipient cancer than where the UGS-
induced bladder cancer has already manifested.15 In 
addition, 8-nitroguanine forms via inducible expression 
of nitric oxide synthase in Oct3/4-positive stem cells in 
UGS-associated bladder cancer tissue,67 and DNA nitra-
tive and oxidative mutations characterized by 8-nitro-
guanine and 8-hydroxy-2′-deoxyguanosine (8-oxodG), 
have been implicated in the promotion of inflammation-
mediated carcinogenesis by infection with S. haemato-
bium.68 Moreover, other studies have shown that UGS is 
likely to cause bladder cancer by this mechanism, and 
noted a correlation between UGS and increase of levels 
of oxidative stress accompanied by continuous DNA 
damage and repair in urothelial carcinomas.20,69 These 
metabolites might damage DNA, for example, by for-
mation of DNA adducts (m/z 624, 716, 738, 803, 817, 
851, and 963) and contribute to intermediate production 
of ROS during formation of catechol compounds 
(Figures 2 and 3). Furthermore, these phenomena may 
explain formation of 8-oxodG derivatives (as illustrated 
in Figure 4), metabolites known from urine during UGS.15
Overexpression of p53 during UGS
The p53 is a tumor suppressor protein involved in diverse 
pathways including regulation of cell cycle, suppression 
of cell proliferation, cellular response to DNA damage, 
Figure 4. DNA damage possibly related to estrogen-like 
metabolites from parasite. Compounds in urine of persons 
infected with the blood fluke S. haematobium with or 
without infection-induced bladder cancer. The compounds 
derive directly from 8-oxodG, a product of DNA oxidation. 
Formation of these molecules may be a consequence of 
interaction with catechol compounds from parasite.
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initiation of DNA repair and replication, induction of apop-
tosis, and promotion of differentiation.27,28,66,70 Dysregulation 
of the expression of p53 gene may accelerate the tumorigen-
esis and alter the response of cellular agents that damage 
DNA.2 Together, the genes encoding these proteins are 
referred to as tumor suppressor genes. Inactivation or altera-
tion in the expression of these genes together with activation 
of oncogenes leads to malignant transformation.71 It has 
been shown that the formation of DNA adducts may be 
related to a high expression of p53 during schistosomia-
sis.28,72,73 Given that (i) S. haematobium produces com-
pounds that react with DNA and damage chromosomal 
DNA, and (ii) p53 mutations have been associated with 
schistosomiasis,28 chronic infection with S. haematobium 
may stimulate the expression of p53 during UGS and UGS-
induced bladder cancer. In addition, p53 is overexpressed 
during UGS, although the molecular mechanisms remain 
unclear,20,23,29,69,74 and p53 protein has been detected by 
immunolocalization in both aggressive urothelial and squa-
mous cell bladder carcinomas. Notably, p53 is mutated and 
not functional in benign/premalignant lesions, predomi-
nantly in those showing cellular alterations, including 
urothelial hyperplasia, epidermoid metaplasia, and/or dys-
plasia.20 This conforms to findings in urine using liquid 
chromatography–mass spectrometry LC-MS/MS during 
UGS, where DNA oxidation processes appear more pro-
nounced in cases with UGS but without cancer.15 The 
eventual association between the dysregulation of p53 in 
urothelium and infection with S. haematobium reinforces 
the notion that UGS profoundly alters in cellular process in 
the urothelium, ultimately giving rise to bladder cancer after 
a continuous accumulation of mutations and selection of 
aggressive clones of transformed cells. By employing a 
model of chemical-induced carcinogenesis of the bladder in 
genetically modified mice, that is, using N-butyl-N-(4-
hydroxybutyl)nitrosamine (BBN), it has been recently dem-
onstrated the cellular origin of the bladder neoplasia.75 In 
this model, invasive carcinoma is initiated from basal 
urothelial stem cells that started to accumulate mutations 
that eventually offer positive selection of aggressive clones 
of cells. The probability of this phenomenon ultimately 
depends on the mutagenesis pressure on the target tissue that 
in the context of UGS where the described estrogen-like 
metabolites are produced may be higher.15
Future perspectives
Carcinogenic transformation of the bladder during UGS 
may proceed along a pathway involving the formation of 
catechol and DNA adducts, intermediary formation of 
ROS, p53 mutations that inhibit the repair of DNA and, in 
turn, initiate carcinogenesis (Box 1). Whereas carcino-
genesis may be induced by other factors,76,77 this is a 
plausible route to UGS-induced SCC. Pathways for for-
mation of these carcinogenic metabolites with parasite 
origin are not yet fully understood. Investigations in this 
field are required to determine specific enzymatic func-
tions of pathogens and whether these correlate with the 
ability of various Schistosoma species to produce bladder 
cancer. The findings hold the promise for new interven-
tions, including prognostic biomarkers and indeed a vac-
cine against this NTD-induced cancer.
Box 1. Outstanding questions.
•• Schistosomiasis is considered the most important of the human helminth diseases in terms of morbidity and mortality. Three 
major species of schistosomes contribute to the affliction-Schistosoma haematobium, S. mansoni, and S. japonicum. However, 
why infection with S. haematobium is carcinogenic whereas infection with other schistosomes is not remains to be resolved.
•• What are the physiological roles of schistosome estradiol-like metabolites for the parasite, in view of their (additional?) 
capacity as carcinogens in bladder cancer during UGS; unfortunate and unwelcome bystander effect?
•• Does the genome of the blood fluke encode the necessary pathways to synthesize endogenous estradiol de novo and/or 
does the blood fluke catabolize and modify hormones of human origin for its purposes?
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